Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity

Lü, Xing; Wu, Yiming; Yang, Jingmei; Ma, Feng'e; Li, Liangping; Chen, Sheng; Zhang, Ye; Ni, Qing-Ling; Pan, Ying‐Ming; Xue, Hong; Peng, Yan

doi:10.1016/j.ejmech.2018.03.074

Cited by 16 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inspired by the reported activity of rhodium complexes and the biological activity of quinoline derivatives, Yan Peng et al designed a class of stable metal complexes with high antitumor activity and hoped that the new Rh(III) complexes could improve the inhibition of enzymes and selectivity 46 . From the MTT results, the Rh(III) complexes ( 47a – e , Figure 11) showed superior antiproliferative activity compared to the ligands and cisplatin, especially complex 47a was less toxic to normal cells and had better selectivity (SI = 3.6).…”

Section: Egfr‐tkis Metal Complexesmentioning

confidence: 99%

Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents

Ma,

Wang,

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

Overexpression of the epidermal growth factor receptor (EGFR, erbB1) has been observed in a wide range of solid tumors and has frequently been associated with poor prognosis. As a result, EGFR inhibition has become an attractive anticancer drug design strategy, and a large number of small molecular inhibitors have been developed. Despite the widespread clinical use of EGFR tyrosine kinase inhibitors (TKIs), their drug resistance, inadequate accumulation in tumors, and severe side effects have spurred the search for better antitumor drugs. Metal complexes have attracted much attention because of their different mechanisms compared with EGFR‐TKIs. Therefore, the combination of metals and inhibitors is a promising anticancer strategy. For example, Ru and Pt centers are introduced to design complexes with double or multiple targets, while Au complexes are combined with inhibitors to overcome drug resistance. Co complexes are designed as prodrugs with weak side effects and enhanced targeting by the hypoxia activation strategy, and other metals such as Rh and Fe enhance the anticancer effect of the complexes. In addition, the introduction of Ga center is beneficial to the development of nuclear imaging tracers. In this paper, metal EGFR‐TKI complexes in the last 15 years are reviewed, their mechanisms are briefly introduced, and their advantages are summarized.

show abstract

Section: Egfr‐tkis Metal Complexesmentioning

confidence: 99%

Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents

Ma,

Wang,

et al. 2024

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…16,27–31 Additionally, a number of researchers have investigated Rh( iii ) complexes based on (iso)quinoline, quinolinone, and 8-hydroxyquinoline ligands. 12,32–44 Some of them have also been tested for their ability to interact with BSA, protein kinases, lysine-specific demethylase 1, DNA, ATP-competitive neural precursor, mitochondria, and other enzymes. 12,32–44 Recently, (iso)quinolone derivative metal complexes have been examined as specific probes and photodynamic therapy reagents, such as 8-hydroxyquinoline Ru( ii )-arene complexes, 45 8-oxychinolin cyclometalated Ir( iii ) complexes, 46 zinc( ii ) phthalocyanine-quinoline derivatives, 47 phenylisoquinoline Ir( iii ) phosphorescent probe, 48,49 near-infrared-emitting Ir( iii ) complexes, 50 luminescent di-2-picolylamine Ir( iii ) complexes, 51 and quinoline–coumarin organoplatinum( ii ) derivatives.…”

Section: Introductionmentioning

confidence: 99%

“…12,32–44 Some of them have also been tested for their ability to interact with BSA, protein kinases, lysine-specific demethylase 1, DNA, ATP-competitive neural precursor, mitochondria, and other enzymes. 12,32–44 Recently, (iso)quinolone derivative metal complexes have been examined as specific probes and photodynamic therapy reagents, such as 8-hydroxyquinoline Ru( ii )-arene complexes, 45 8-oxychinolin cyclometalated Ir( iii ) complexes, 46 zinc( ii ) phthalocyanine-quinoline derivatives, 47 phenylisoquinoline Ir( iii ) phosphorescent probe, 48,49 near-infrared-emitting Ir( iii ) complexes, 50 luminescent di-2-picolylamine Ir( iii ) complexes, 51 and quinoline–coumarin organoplatinum( ii ) derivatives. 52 a Although a few metal-(iso)quinolone compounds have recently been used in mitochondrial and other imaging experiments, rhodium( iii ) metal complexes bearing quinoline–benzopyran ligands (QB1–QB4) have not yet been studied for such imaging and anticancer therapeutics in cell nucleus fractions, to the best of our knowledge.…”

Section: Introductionmentioning

confidence: 99%

Cell nucleus localization and high anticancer activity of quinoline–benzopyran rhodium(iii) metal complexes as therapeutic and fluorescence imaging agents

Wang

Nai

et al. 2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

Synthesis and anticancer activities of novel Pt (II) and Pd (II) complexes with 4‐(2,2′:6′,2″‐terpyridin‐4′‐yl)phenol as ligand

Yao

et al. 2023

Applied Organom Chemis

View full text Add to dashboard Cite

Traditional platinum (Pt)‐based drugs have limited use in cancer treatment because of their toxicity, which generates the need for new Pt complexes with effective anticancer activity. Two potent prospective anticancer small molecule drug complexes, PtLCl (1) and PdLCl (2) (L:4‐[2,2′:6′,2′‐terpyridin‐4′‐yl]phenol), were synthesized via a low‐temperature solvothermal method. The structures of the complexes are characterized by a four‐coordinated rhombus plane, according to single‐crystal X‐ray diffraction studies. The complexes 1 and 2 were further characterized using several techniques including powder X‐ray diffraction, infrared spectroscopy, and cyclic voltammetry. Cytotoxicity was assessed using flow cytometry and morphological observations of HeLa cells. The findings demonstrate that both complexes were highly effective at inducing cell death, and the tumor inhibition rate of 1 was greater than that of 2, with total tumor inhibition of 92.3% and 72.3%, respectively, after 24 h. In addition, fluorescence and UV–vis spectroscopy showed that these complexes interacted with DNA through the embedding methods. The four‐coordinated planar structure and π–π stacking could prevent DNA transfer and replication, which has the potential for more effective cancer cell eradication through intercalation. Therefore, these two complexes are promising candidates for the development of new Pt‐ and Pd‐based anticancer drugs.

show abstract

Preparation of Rhodium(III) complexes with 2(1H)-quinolinone derivatives and evaluation of their in vitro and in vivo antitumor activity

Cited by 16 publications

References 38 publications

Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents

Metal complexes bearing EGFR‐inhibiting ligands as promising anticancer agents

Cell nucleus localization and high anticancer activity of quinoline–benzopyran rhodium(iii) metal complexes as therapeutic and fluorescence imaging agents

Synthesis and anticancer activities of novel Pt (II) and Pd (II) complexes with 4‐(2,2′:6′,2″‐terpyridin‐4′‐yl)phenol as ligand

Contact Info

Product

Resources

About